Cross-sectional study assesses branded and generic dapagliflozin use, highlighting financial impacts for Medicaid.
This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.
No takes yet. Share an insight, caveat, or question.
El-Kilani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: